Antimicrobial resistance of Gram negative bacilli isolated from terciary-care hospitals in Colombia;Actualización de la resistencia a antimicrobianos de bacilos Gram negativos aislados en hospitales de nivel III de Colombia: Años 2006, 2007 y 2008

Biomedica

Volumn 30, Issue 3, 2010, Pages 371-381

  Briceño, David Felipe ^a   Correa, Adriana ^a   Valencia, Carlos ^a   Torres, Julián Andrés ^a   Pacheco, Robinson ^a   Montealegre, María Camila ^a   Ospina, Diego ^a   Villegas, María Virginia ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

Bacterial; Colombia; Drug resistance; Epidemiologic surveillance; Gram negative bacteria

Indexed keywords

ACINETOBACTER BAUMANNII; BACILLI (CLASS); BACTERIA (MICROORGANISMS); ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 78650061835     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v30i3.271     Document Type: Article

References (33)

1. World Health Organization. WHO Global strategy for containment of antimicrobial resistance. WHO/CDS/CSR/DRS/2001.2.Geneva: WHO; 2001.
2. Critchley IA, Karlowsky JA. Optimal use of antibiotic resistance surveillance systems. Clin Microbiol Infect. 2004;10:502-11.
3. Tokars JI, Richards C, Andrus M, Klevens M, Curtis A, Horan T, et al. The changing face of surveillance for health care-associated infections. Clin Infect Dis. 2004;39:1347-52.
4. Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis. 2005;53:247-56.
5. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008;46:1121-2.
6. Masterton R. The importance and future of antimicrobial surveillance studies. Clin Infect Dis. 2008;47(Suppl.1):S21-31.
7. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462-74.
8. Leal AL, Eslava-Schmalbach J, Álvarez C, Buitrago G, Méndez M. Endemic tendencies and bacterial resistance markers in third-level hospitals in Bogotá, Colombia. Rev Salud Pública (Bogotá). 2006;8(Suppl.1):59-70.
9. Villegas MV, Correa A, Pérez F, Miranda MC, Zuluaga T, Quinn JP, et al. Prevalence and characterization of extended-spectrum β-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagn Microbiol Infect Dis. 2004;49:217-22.
10. Villegas MV, Lolans K, Correa A, Suárez CJ, López JA, Vallejo M, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50:2880-2.
11. Villegas MV, Kattan JN, Correa A, Lolans K, Guzmán AM, Woodford N, et al. Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrob Agents Chemother. 2007;5:2001-4.
12. Miranda MC, Pérez F, Zuluaga T, Olivera MR, Correa A, Reyes SL, et al. Resistencia a antimicrobianos en bacilos Gram negativos aislados en unidades de cuidado intensivo en hospitales de Colombia, WHONET 2003, 2004 y 2005. Biomédica. 2006;26:424-33.
13. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-32.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 19th Informational Supplement. CLSI document M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
15. Stelling JM, O'Brien TF. Surveillance of antimicrobial resistance: the WHONET program. Clin Infect Dis. 1997;24(Suppl.1):S157-68.
16. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med. 2003;24:121-34.
17. Quinn JP. Pseudomonas aeruginosa infections in the intensive care unit. Semin Respir Crit Care Med. 2003;24:61-8.
18. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother. 2008;52: 813-21.
19. Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 2006;14:413-20.
20. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005;49:2137-9.
21. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280:1233-7.
22. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 1996;23:118-24.
23. Lucet JC, Decre D, Fichelle A, Joly-Guillou ML, Pernet M, Deblangy C, et al. Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriaceae in a university hospital. Clin Infect Dis. 1999;29:1411-8.
24. Chow J, Fine M, Shlaes D, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585-90.
25. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161-82.
26. Villegas MV, Lolans K, Correa A, Kattan JN, López JA, Quinn JP. First Identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob Agents Chemother. 2007;5:1553-5.
27. Paterson DL, Ko WC, Von GA, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis. 2004;39:31-7.
28. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis. 2009;49:291-8.
29. Oudhuis GJ, Verbon A, Hoogkamp-Korstanje JA, Stobberingh EE. Antimicrobial resistance in Escherichia coli and Pseudomonas aeruginosa from intensive care units in The Netherlands, 1998-2005. Int J Antimicrob Agents. 2008;31:58-63.
30. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(Suppl.2):S146-55.
31. Paterson DL. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis. 2006;42(Suppl.2):S90-5.
32. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001;29:1109-15.
33. File TM. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J Manag Care Pharm. 2009;15(Suppl.V):S5-11.